199 related articles for article (PubMed ID: 22931656)
21. [Prognostic evaluation in multiple myeloma. Relationship between immunological types, single prognostic factors, clinical staging systems, morphological classification systems and survival].
Pasqualetti P; Colantonio D; Casale R; Di Lauro G; Collacciani A; Festuccia V; Trotta A; Natali G
Ann Ital Med Int; 1990; 5(3 Pt 1):195-204. PubMed ID: 2288822
[TBL] [Abstract][Full Text] [Related]
22. Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma.
Ailawadhi S; Abdelhalim AN; Derby L; Mashtare TL; Miller KC; Wilding GE; Alberico RA; Gottlieb R; Klippenstein DL; Lee K; Chanan-Khan AA
Cancer; 2010 Jan; 116(1):84-92. PubMed ID: 19862816
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors in multiple myeloma: selection using Cox's proportional hazard model.
Pasqualetti P; Collacciani A; Maccarone C; Casale R
Biomed Pharmacother; 1996; 50(1):29-35. PubMed ID: 8672729
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors in multiple myeloma: definition of risk groups in 410 previously untreated patients: a Grupo Argentino de Tratamiento de la Leucemia Aguda study.
Corrado C; Santarelli MT; Pavlovsky S; Pizzolato M
J Clin Oncol; 1989 Dec; 7(12):1839-44. PubMed ID: 2585023
[TBL] [Abstract][Full Text] [Related]
25. Myeloma cell morphology and morphometry in correlation with clinical stages and survival.
Seili-Bekafigo I; Valković T; Babarović E; Duletić-Načinović A; Jonjić N
Diagn Cytopathol; 2013 Nov; 41(11):947-54. PubMed ID: 23554178
[TBL] [Abstract][Full Text] [Related]
26. Prognostic factors and staging in multiple myeloma: a reappraisal.
Bataille R; Durie BG; Grenier J; Sany J
J Clin Oncol; 1986 Jan; 4(1):80-7. PubMed ID: 3510284
[TBL] [Abstract][Full Text] [Related]
27. A comparison of two staging systems for myeloma.
Vercelli D; Cozzolino F; Di Guglielmo R
Nouv Rev Fr Hematol (1978); 1981; 23(2):107-10. PubMed ID: 7290984
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive analysis and establishment of a prognostic model based on non-genetic predictors in multiple myeloma.
Lu W; Xu S; Tan S; Lu L; Luo M; Xiao M
Cancer Biomark; 2023; 38(1):49-59. PubMed ID: 37522196
[TBL] [Abstract][Full Text] [Related]
29. Comparison among immunologically different subtypes of 595 untreated multiple myeloma patients in northern China.
Zhang L; Qi JY; Qi PJ; Wang YF; Zou DH; Yao HJ; An G; Yi SH; Li Q; Qiu LG
Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):197-204. PubMed ID: 20511165
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters.
Bhatti SS; Kumar L; Dinda AK; Dawar R
Am J Hematol; 2006 Sep; 81(9):649-56. PubMed ID: 16845660
[TBL] [Abstract][Full Text] [Related]
31. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience.
Jacobson JL; Hussein MA; Barlogie B; Durie BG; Crowley JJ;
Br J Haematol; 2003 Aug; 122(3):441-50. PubMed ID: 12877671
[TBL] [Abstract][Full Text] [Related]
32. [Survival prognosis factors in multiple myeloma].
Younes M; Hachfi H; Hammouda F; Younes K; Ben Hammouda S; Jguirim M; Zrour S; Béjia I; Touzi M; Bergaoui N
Tunis Med; 2014 Jun; 92(6):399-405. PubMed ID: 25741841
[TBL] [Abstract][Full Text] [Related]
33. Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma.
Jakob C; Sterz J; Liebisch P; Mieth M; Rademacher J; Goerke A; Heider U; Fleissner C; Kaiser M; von Metzler I; Müller C; Sezer O
Leukemia; 2008 Sep; 22(9):1767-72. PubMed ID: 18580957
[TBL] [Abstract][Full Text] [Related]
34. New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy.
Kim H; Sohn HJ; Kim S; Kim K; Lee JH; Bang SM; Kim DH; Sohn SK; Lee JJ; Suh C
Biol Blood Marrow Transplant; 2006 Aug; 12(8):837-44. PubMed ID: 16864054
[TBL] [Abstract][Full Text] [Related]
35. Analysis of clinical characteristics and prognostic factors of multiple myeloma: a retrospective single-center study of 787 cases.
Qian J; Jin J; Luo H; Jin C; Wang L; Qian W; Meng H
Hematology; 2017 Sep; 22(8):472-476. PubMed ID: 28463078
[TBL] [Abstract][Full Text] [Related]
36. The international staging system for multiple myeloma is applicable in symptomatic Waldenstrom's macroglobulinemia.
Dimopoulos M; Gika D; Zervas K; Kyrtsonis M; Symeonidis A; Anagnostopoulos A; Bourantas K; Matsouka C; Pangalis G
Leuk Lymphoma; 2004 Sep; 45(9):1809-13. PubMed ID: 15223640
[TBL] [Abstract][Full Text] [Related]
37. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
38. High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment.
Urbańska-Ryś H; Robak T
Mediators Inflamm; 2003 Aug; 12(4):229-35. PubMed ID: 14514474
[TBL] [Abstract][Full Text] [Related]
39. Prognostic variables and clinical staging in multiple myeloma.
Cavo M; Galieni P; Zuffa E; Baccarani M; Gobbi M; Tura S
Blood; 1989 Oct; 74(5):1774-80. PubMed ID: 2790201
[TBL] [Abstract][Full Text] [Related]
40. [Prognostic factors of multiple myeloma].
Paule B
Ann Med Interne (Paris); 1997; 148(8):534-41. PubMed ID: 9538400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
